New progress in cancer treatment based on monoclonal antibodies

Monoclonal antibodies (mAbs) have emerged as a promising approach in cancer treatment, offering high specificity, fewer adverse reactions, and improved prognoses compared to traditional chemotherapy and radiotherapy. These drugs utilize monoclonal antibodies to precisely target and bind to cancer-specific markers, enhancing treatment efficacy. Since the approval of the first monoclonal antibody drug in 1986, the field has expanded significantly, with thousands of such drugs now available globally. In China, 53 mAbs have been approved as of 2021. Despite these advances, challenges such as drug resistance and high costs remain. However, continued scientific research and technological innovation are expected to address these issues and further improve treatment outcomes. The integration of individualized treatment plans, tailored to the specific characteristics of patients' tumors, holds the potential to revolutionize cancer care. With ongoing clinical trials and research, mAbs are expected to play an increasingly vital role in cancer therapy, offering new hope to patients and contributing to the global fight against this life-threatening disease.